Dysis Medical, a UK-based medical devices company to treat cervical cancer formerly known as Forth Photonics, has raised £7.4m ($11.3m) from a consortium including Lundbeckfond Ventures, the quasi-corporate venturing unit of the eponymous Denmark-based foundation that owns large stakes in local healthcare companies.

Lundbeckfond Ventures invested £6m as a new investor with the other investors in the round included venture capital firms Albion Ventures and NBGI and the Scottish Investment Bank (SIB), the investment unit of state-backed Scottish Enterprise.
In February 2009, Dysis, when known as Forth, previously raised £6.1m.

Mikael Strindlund and Casper Breum from Lundbeckfond Ventures, which invests about $70m each year as an evergreen fund, joined Dysis’s board. Strindlund said: “Dysis Medical’s technology offers substantial clinical benefits in the fight against cervical cancer as well as improved cost-effectiveness over existing care.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?